
Donanemab: A New Ray of Hope in the Fight Against Alzheimer's
The Brain Health Revolution Podcast
Eli Lilly's Donanemab: A New Alzheimer's Drug
This chapter discusses Eli Lilly's new Alzheimer's drug called Donanemab, a monoclonal antibody that targets the toxic amyloid beta protein in the brain. It explores the controversy surrounding the role of amyloid in Alzheimer's disease and introduces a study on the effects of Donanemab in individuals with early Alzheimer's. The chapter also highlights the importance of properly communicating the results and addressing potential side effects.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.